Design Therapeutics, Inc. - Common Stock (DSGN)

Q2 2021 13F Holders as of 30 Jun 2021

Type / Class
Equity / Common Stock
Shares outstanding
57,159,091
Total 13F shares
27,832,674
Share change
+2,091,378
Total reported value
$546,067,000
Price per share
$19.89
Number of holders
48
Value change
+$37,361,092
Number of buys
30
Number of sells
16

Institutional Holders of Design Therapeutics, Inc. - Common Stock (DSGN) as of Q2 2021

As of 30 Jun 2021 Design Therapeutics, Inc. - Common Stock (DSGN) had 48 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions held a total of 27,832,674 shares of stock of the company.
Largest 10 holders included Cormorant Asset Management, LP, Logos Global Management LP, CITADEL ADVISORS LLC, RA CAPITAL MANAGEMENT, L.P., Avoro Capital Advisors LLC, PRICE T ROWE ASSOCIATES INC /MD/, BAKER BROS. ADVISORS LP, BlackRock Inc., EcoR1 Capital, LLC, and VANGUARD GROUP INC.
This table shows 48 institutional shareholders of the security as of 30 Jun 2021.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.